Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients

NCT03961009 is registered in ClinicalTrials.gov with Kedrion S.p.A. as lead sponsor.

NCT NCT03961009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03961009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients
Lead sponsor
Kedrion S.p.A.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2019
Completion date
December 21, 2020
Enrollment
47 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency disease